M&A Corner
Pairwise, Bayer Build on Successful Gene Editing Partnership With New Five-Year, Multi-Million Dollar Collaboration to Further Advance Short-Stature Corn05 Sep 2023
Food and agriculture company Pairwise and Bayer have entered into a new five-year, multi-million-dollar agreement to focus on innovations in... Continue Reading
|
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m.05 Sep 2023
Opthea Limited, a medical company, has successfully completed its institutional capital raising, generating approximately A$73.7 million. This included a non-underwritten... Continue Reading
|
3B Scientific Acquires iNNOGING Medical.05 Sep 2023
3B Scientific, a prominent medical simulation product manufacturer, is set to acquire iNNOGING Medical, a company specializing in cloud-based SaaS... Continue Reading
|
Specialised Therapeutics Acquires Commercialisation Rights to New Oral MND therapy05 Sep 2023
Specialised Therapeutics Asia and Treeway BV are partnering to introduce a new ALS therapy, TW001, in Australia and New Zealand.... Continue Reading
|
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®29 Aug 2023
Bausch + Lomb Corporation’s acquisition of XIIDRA, a non-steroid eye drop approved for treating dry eye disease, has cleared the... Continue Reading
|
Bionoid Pharma Extends Letter of Intent to Acquire Global Alerts Corp.29 Aug 2023
Bionoid Pharma (BINP) has extended the effective period of a Letter of Intent (LOI) with Global Alerts Corp. The original... Continue Reading
|
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR29 Aug 2023
GRI Bio has entered an asset purchase agreement with Aardvark Therapeutics for the acquisition of specific assets and intellectual property... Continue Reading
|
Pyxis Oncology Successfully Completes Acquisition of Apexigen29 Aug 2023
Pyxis Oncology has successfully completed its acquisition of Apexigen, a clinical-stage biopharmaceutical company, in an all-stock transaction valued at about... Continue Reading
|
APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II29 Aug 2023
APRINOIA Therapeutics has announced the mutual termination of its business combination agreement with Ross Acquisition Corp II (RAC), a special... Continue Reading
|
NorthX Biologics Welcomes Dr Janet Hoogstraate as New CEO Following Merger with Valneva Clinical Trials Manufacturing Unit.29 Aug 2023
Dr. Janet Hoogstraate has been appointed as the new Chief Executive Officer of NorthX Biologics AB, a Nordic development and... Continue Reading
|